USP33 and pulmonary tuberculosis: Notably, bedaquiline—an established inhibitor of adenosine triphosphate (ATP) synthase in drug-resistant pulmonary tuberculosis (72)—was identified as a candidate inverter of USP33 and CUL5 activity.